Found 205 articles
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
Merck and Ridgeback Biotherapeutics today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the refusal of the marketing authorization for LAGEVRIO™ (molnupiravir) for the treatment of certain adults who have been diagnosed with COVID-19 in the European Union (EU).
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19.
NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending December 31, 2022 with the Securities and Exchange Commission on Tuesday, February 14, 2023.
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.
Merck Announces Third-Quarter 2022 Financial Results
Merck, known as MSD outside the United States and Canada, announced financial results for the third quarter of 2022.
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today issued the following announcement regarding data from two real-world evidence studies evaluating LAGEVRIO™ (molnupiravir), an investigational oral antiviral COVID-19 medicine.
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022.
Merck Announces Second-Quarter 2022 Financial Results
Merck, known as MSD outside the United States and Canada, announced financial results for the second quarter of 2022. This press release features multimedia.
Oral Solid Dosage Pharmaceutical Market Landscape Dominated By Immediate Drug Release Mechanism: Fact.MR Study
Fact.MR – A Market Research and Competitive Intelligence Provider: The global oral solid dosage pharmaceutical market is set to experience robust growth at 6.4% CAGR and cross a market valuation of US$ 1 trillion by the end of 2032.
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga™ (Ansuvimab-zykl).
Even though the COVID-19 pandemic appears to be under control, it's clear that it's not over, with the rise of more subvariants. Read on for more details.
Powered by its blockbuster checkpoint inhibitor Keytruda, Merck is forecasting a potential of more than 80 new regulatory approvals in oncology through 2028.
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO ™ (molnupiravir) From Phase 3 MOVe-OUT Study.
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
Pfizer apparently hasn't begun any combination trials in human beings of Paxlovid, and no reported human tests are using the drug in combination with other therapies.
Gilead’s Veklury made massive profits, but as more vaccine boosters arrive and more people become immune to the virus, the future of the antiviral is in question.
Merck held a conference call Thursday morning to discuss its Q1 2022 earnings. The company reported a 50% growth in revenue, increasing its worldwide sales to $15.9 billion.
Merck Announces First-Quarter 2022 Financial Results
Merck, known as MSD outside the United States and Canada, announced financial results for the first quarter of 2022.
Long COVID is loosely defined as COVID-19 symptoms that persist for longer than four weeks from an initial diagnosis. Here’s a look at the latest in long COVID research.
Veru posted positive interim Phase III data from its late-stage study assessing oral antiviral sabizabulin in hospitalized COVID-19 patients. Here's more about it.